Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research

A. Mahindra, M. E. Kalaycio, J. Vela-Ojeda, D. H. Vesole, M. J. Zhang, P. Li, J. R. Berenson, J. M. Bird, A. Dispenzieri, J. L. Gajewski, R. P. Gale, L. Holmberg, S. Kumar, R. A. Kyle, H. M. Lazarus, S. Lonial, J. Mikhael, G. A. Milone, R. Munker, R. NathS. Saccaro, L. B. To, D. T. Vogl, B. Wirk, P. Hari

    Research output: Contribution to journalArticle

    53 Scopus citations

    Abstract

    There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

    Original languageEnglish (US)
    Pages (from-to)1091-1097
    Number of pages7
    JournalLeukemia
    Volume26
    Issue number5
    DOIs
    StatePublished - May 2012

    Keywords

    • Primary plasma cell leukemia
    • overall survival
    • stem cell transplant

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research'. Together they form a unique fingerprint.

  • Cite this

    Mahindra, A., Kalaycio, M. E., Vela-Ojeda, J., Vesole, D. H., Zhang, M. J., Li, P., Berenson, J. R., Bird, J. M., Dispenzieri, A., Gajewski, J. L., Gale, R. P., Holmberg, L., Kumar, S., Kyle, R. A., Lazarus, H. M., Lonial, S., Mikhael, J., Milone, G. A., Munker, R., ... Hari, P. (2012). Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research. Leukemia, 26(5), 1091-1097. https://doi.org/10.1038/leu.2011.312